Randomized controlled trial evaluates imaging measures in giant cell arteritis, suggesting future exploration is needed.
Vascular FDG-PET activity may be discordant with clinical assessment, particularly in subsets of patients with GCA. Imaging-based outcome measures should remain exploratory in future therapeutic trials.
No takes yet. Share an insight, caveat, or question.
Quinn et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: